Caribou Biosciences stock analysis
Want to see CRBU full AI Analyst Report?
Caribou Biosciences (CRBU) Stock Price & Analysis
CRBU Stock Chart & Stats
- Day’s Range
- $0.35 - $0.36
- 52-Week Range
- $0.35 - $2.49
- Previous Close
- $0.36
- Volume
- N/A
- Average Volume (3M)
- 4.63M
- Market Cap
- $39.10M
- Enterprise Value
- $68.11M
- Total Cash (Recent Filing)
- $94.80M
- Total Debt (Recent Filing)
- $26.34M
- Price to Earnings (P/E)
- ―
- Beta
- 1.92
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- -0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross Margin
The approximately 92% TTM gross margin indicates favorable economics at the gross-profit level and substantial value capture from current revenue. If maintained, this provides a foundation for operating leverage as programs advance, although the benefit is currently overwhelmed by substantial operating expenses.
Genome-Editing Platform
The CRISPR-based platform and focus on allogeneic, off-the-shelf immune cells provide a differentiated technology foundation within oncology cell therapy. A reusable editing platform can support multiple candidates and potentially broaden future development opportunities beyond a single product.
Manageable Leverage
Debt-to-equity of approximately 0.34 indicates that leverage is not currently excessive relative to the company’s capital base. This offers some financial flexibility compared with a highly debt-funded structure, even though ongoing losses and declining equity remain important constraints on that flexibility.
Bears Say
Severe Operating Losses
The scale of operating losses relative to revenue shows that CRBU has not yet established a self-sustaining commercial model. Continued high operating expenses can consume capital faster than the business builds revenue, making future progress dependent on successful pipeline execution and additional financing capacity.
Persistent Cash Burn
Operating and free cash flow of approximately negative $93 million demonstrate that the company remains materially dependent on its cash reserves or external capital. Although burn improved from prior periods, the still-negative result limits funding flexibility and leaves less capacity to absorb setbacks or support broad development activity.
Program Retrenchment
Discontinuing two key allogeneic CAR-T programs and reducing the workforce materially narrows the active pipeline and signals a major strategic retrenchment. The associated trial wind-downs, contract changes, and restructuring charges may reduce near-term operating capacity while management evaluates strategic alternatives.
Caribou Biosciences News
Caribou to discontinue development activities, explore alternatives
Caribou Biosciences (CRBU) announced that it is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
What is Caribou Biosciences’s market cap?
When is Caribou Biosciences’s upcoming earnings report date?
How were Caribou Biosciences’s earnings last quarter?
Is Caribou Biosciences overvalued?
Does Caribou Biosciences pay dividends?
What is Caribou Biosciences’s EPS estimate?
How many shares outstanding does Caribou Biosciences have?
What happened to Caribou Biosciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Caribou Biosciences?
What is the TipRanks Smart Score and how is it calculated?
Caribou Biosciences Stock Smart Score
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rachel E. Haurwitz
- Employees
- 97
- Website
- cariboubio.com
- Address
- 2929 7th Street, Berkeley, CA, 94710, US
Caribou Biosciences (CRBU) Earnings & Revenues
CRBU Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 1 | 16 |
| Technical Analysis | 5 | 1 | 4 |
| Moving Averages | 0 | 0 | 12 |












